Daily non-political popular news in brief.

Is there a role for serial outpatient drug infusions in advanced heart failure?

03-25-2007 · EurekAlert!

For patients with severe chronic heart failure, known as stage D or chronic decompensated heart failure (CDHF), hospitalization is frequent and treatment options are limited. The FUSION II trial (Follow-Up Serial Infusions of Nesiritide in Advanced Heart Failure) tested the benefit of a novel drug infusion regimen of serial administration of nesiritide (NES) versus placebo in outpatients with advanced heart failure and a primary endpoint of all cause mortality and cardiorenal hospitalizations.

Keywords: role, serial, outpatient, drug, infusions, advanced, heart, failure, infusion

« Previous | Next »

Similar news on "Is there a role for serial outpatient drug infusions in advanced heart failure?":

Advance in understanding of blood pressure gene could lead to new treatments
02-04-2007 · EurekAlert!
Research by scientists at UCL (University College London) has clearly demonstrated for the first time the structure and function of a gene crucial to the regulation of blood pressure. The discovery could be important in the search for new treatments for illnesses such as heart disease, the UK's biggest killer. In a paper published online today in Nature Medicine, the team, led by Professor Patrick Vallance and Dr James Leiper, UCL Department of Medicine, reveal the role of the human gene dimethylarginine dimethylaminohydrolase (DDAH), showing that loss of DDAH activity disrupts nitric oxide (NO) production. NO is critical in the regulation of blood pressure, nervous system functions and the immune system. The role of DDAH is to break down modified amino acids (Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA)) that are produced by the body and have been shown to inhibit NO synthase. These molecules accumulate in various disease states including diabetes, renal failure and pulmonary and systemic hypertension, and their concentration in plasma (the fluid component of blood) is strongly predicative of cardiovascular disease and death. In a healthy human body, the majority of ADMA is eliminated through active metabolism by DDAH. Scientists have hypothesised that if DDAH function is impaired, NO production is reduced, and that this could be an important feature of increased cardiovascular risk. To examine this pathway in more detail, the researchers deleted the DDAH gene in mice. These mice went on to develop hypertension, or high blood pressure. They also designed specific inhibitors (small molecules) which bind to the active site of human DDAH. These small molecule inhibitors also induced hypertension in mice, confirming the importance of DDAH in the regulation of blood pressure. Dr Leiper, UCL Medicine, said: “These genetic and chemical approaches to disrupt DDAH showed remarkably consistent results, and provide compelling evidence that loss of DDAH function increases the concentration of ADMA and thereby disrupts vascular NO signalling. “There has been considerable scientific interest in this pathway and the role of ADMA as a novel risk factor, but so far there's been little evidence to support the idea that it's a cause of disease, rather than just a marker. Genes and their pathways are crucial to our understanding of cardiovascular disease and a better understanding of DDAH-1 could lead to important new treatments. “It could help us to establish if genetic variation predisposes certain people to these diseases, or whether environmental factors exert some of their effects through modulation of DDAH activity. “Our research also shows that this pathway could be harnessed therapeutically to limit production of NO in certain situations where too much nitric oxide is a bad thing; for example, hypotension and septic shock. These are some of the biggest problems in intensive care medicine and there is a huge unmet need for drug treatments.” The study, which was carried out at UCL's Rayne Institute, was funded by grants from the British Heart Foundation, the Wellcome Trust and the Medical Research Council. Professor Jeremy Pearson, Associate Medical Director of the British Heart Foundation, said: "The unexpected finding in the 1980s that a simple gas, nitric oxide (NO), is made by cells in the blood vessel wall and is a powerful control of blood vessel relaxation led to the award of the Nobel Prize in 1998 to its discoverers. "More recently, there has been increasing evidence that impairment of NO production is likely to be an important factor in the development of heart and circulatory disease, but the mechanisms responsible are not fully understood. "This study suggests for the first time that the loss of the activity of the enzyme DDAH-1 leads to reduced NO production and may cause heart and circulatory disease. These findings are likely to be important in the search for new ways to optimise the health of our blood vessels." ### Notes for Editors 1. For more information, please contact Ruth Metcalfe in the UCL Media Relations Office on tel: +44 (0)20 7679 9739, mobile: +44 (0)7990 675 947, out of hours: +44 (0)7917 271 364, e-mail: r.metcalfe@ucl.ac.uk2. 'Disruption of methylarginine metabolism impairs vascular homeostasis' is published in the February issue of the journal Nature Medicine. Advance online publication is embargoed to 18.00 GMT (13.00 US Eastern) Sunday 4 February 2007. Journalists can obtain copies of the paper by contacting the UCL Media Relations Office.3. The study was funded by the British Heart Foundation, the Wellcome Trust and the Medical Research Council. About UCL Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the government's most recent Research Assessment Exercise, 59 UCL departments achieved top ratings of 5* and 5, indicating research quality of international excellence. UCL is the fourth-ranked UK university in the 2006 league table of the top 500 world universities produced by the Shanghai Jiao Tong University. UCL alumni include Mahatma Gandhi (Laws 1889, Indian political and spiritual leader); Jonathan Dimbleby (Philosophy 1969, writer and television presenter); Junichiro Koizumi (Economics 1969, Prime Minister of Japan); Lord Woolf (Laws 1954, Lord Chief Justice of England & Wales); Alexander Graham Bell (Phonetics 1860s, inventor of the telephone), and members of the band Coldplay.
Similar news · Read more »
Taking heart failure to the MAT1
02-06-2007 · EurekAlert!
A gene called ménage-à-trois 1, or MAT1, plays a crucial role in the function of a master switch for production of energy in the heart cell -- a finding that has important implications for understanding and maybe even treating heart failure.
Similar news · Read more »
Certain infusion therapy after heart attack does not appear to be beneficial, may cause harm
11-27-2007 · EurekAlert!
Infusion of a combination therapy consisting of glucose, insulin, and potassium, which was thought could be a beneficial treatment immediately following a heart attack, may increase the risk of heart failure and death in the first 3 days for patients with ST-segment elevation myocardial infarction, according to a study in the Nov. 28 issue of JAMA.
Similar news · Read more »
ECLIPSE data on effects of Otsuka's investigational novel treatment, Tolvaptan
09-19-2007 · EurekAlert!
A single dose of Otsuka's investigational oral medication tolvaptan, a vasopressin receptor antagonist, resulted in favorable changes in hemodynamics associated with a significant increase in urine output in patients with advanced heart failure who participated in the international trial the EffeCt of ToLvaptan on HemodynamIc Parameters in Subjects with HEart failure, presented at the late breaking trials symposium of the Heart Failure Society of America's Annual Scientific Meeting.
Similar news · Read more »
Wide UK variation in use of adult heart drug given to children
03-14-2007 · EurekAlert!
The amount and formulation of an adult heart drug given to children with congenital heart failure varies widely across the UK, reveals a survey published ahead of print in the Archives of Disease in Childhood.
Similar news · Read more »
Study finds heart failure is rare among leukemia patients on imatinib
09-06-2007 · EurekAlert!
Congestive heart failure rarely occurs among leukemia patients who take imatinib, researchers at the University of Texas M. D. Anderson Cancer Center found after an exhaustive review of the detailed medical histories of 1,276 patients who enrolled in clinical trials for the drug.
Similar news · Read more »
Long-term use of diabetes drug increases heart attack risk by more than 40 percent
09-11-2007 · EurekAlert!
An analysis of four studies involving more than 14,000 patients found that long-term use of the diabetes drug rosiglitazone (Avandia) increased the risk of heart attack by 42 percent and doubled the risk of heart failure, according to a new report from researchers at Wake Forest University School of Medicine and colleagues. There was no effect on death from cardiovascular causes.
Similar news · Read more »
Drug used for treatment for heart failure in adults may not be beneficial for children and teens
09-11-2007 · EurekAlert!
Preliminary findings indicate a heart failure medication used by adults, carvedilol, may not significantly improve heart failure outcomes for children and adolescents, according to an article in the Sept. 12 issue of JAMA.
Similar news · Read more »
Drug's potential adverse side effect explained
09-06-2007 · EurekAlert!
Drugs that are agonists of the receptor PPAR-gamma are used to treat individuals with diabetes. However, it has been suggested that their use is associated with a slightly increased risk of heart failure. A potential explanation for this adverse effect that is observed in a minority of patients is outlined in a new study in the Journal of Clinical Investigation.
Similar news · Read more »
JCI table of contents -- April 5, 2007
04-05-2007 · EurekAlert!
This release contains summaries, links to PDFs and contact information for the following newsworthy papers to be published online, April 5, 2006, in the JCI, including: Tumors stopped from spreading to new sites; Leptin gives itself some negative feedback; Role for STARS in heart failure illuminated; Learning the normal functions of EWS; and To inhibit or not to inhibit Gi proteins in asthma?
Similar news · Read more »